Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Homewood, Alabama Clinical Trials

A listing of Homewood, Alabama clinical trials actively recruiting patient volunteers.

RESULTS

Found (888) clinical trials

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

Phase

0.0 miles

Learn More »

Effect of Mepolizumab in Severe Bilateral Nasal Polyps

Nasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. This disease is characterized by the presence of polyps in the upper nasal cavity, originating from within the ostiomeatal complex. The presence of polyps can cause long-term symptoms such as prominent nasal obstruction, post-nasal drip, ...

Phase

0.37 miles

Learn More »

From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings

TExT-ME is a home-based tele-exercise study providing a novel exercise program to participants with neurologic disabilities. The exercise curriculum is a Movement 2 Music (M2M) program developed during phase 2 of the grant (clinicaltrials.gov identifier NCT02533882). The exercise exercise classes are taught by trained dance instructors and are composed of ...

Phase N/A

0.37 miles

Learn More »

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.

Phase

0.37 miles

Learn More »

An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

The overall purpose of this study is to evaluate the safety, efficacy, and durability of response of omalizumab in an open-label setting in adult participants with chronic rhinosinusitis with nasal polyps who completed the double-blind, placebo-controlled, Phase III Study GA39688 or GA39855. Participants will be eligible for enrollment in the ...

Phase

0.37 miles

Learn More »

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

The total study duration per patient is expected to be up to 68 weeks that will consist of a 4-week run-in period, 52-week treatment period, and a 12-week posttreatment period.

Phase

0.62 miles

Learn More »

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

This study is to evaluate the safety and efficacy of Fluticasone Propionate and Fluticasone propionate Salmeterol in pediatric patients with a documented history of persistent asthma.

Phase

0.62 miles

Learn More »

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels 500 mg/dL and <2000 mg/dL and normal renal function.

Phase

0.62 miles

Learn More »

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients With Fasting High Triglyceride Levels 500 mg/dL and <2000 mg/dL and Mild or Moderate Renal Impairment.

Phase

0.62 miles

Learn More »

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID). A total of 45 subjects (including at least 14 [30%] pediatric subjects 17 years of age and at least 9 [20%] obese subjects with body ...

Phase

0.62 miles

Learn More »